{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:14:35Z","timestamp":1791101675416,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1124\/dmd.107.017459","type":"journal-article","created":{"date-parts":[[2007,9,7]],"date-time":"2007-09-07T00:39:36Z","timestamp":1189125576000},"page":"2166-2176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor"],"prefix":"10.1016","volume":"35","author":[{"given":"Akihiro","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Shiroyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayakazu","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.017459_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","article-title":"Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide","volume":"18","author":"Hasegawa","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.107.017459_bib2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1124\/jpet.102.046847","article-title":"Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat","volume":"305","author":"Hasegawa","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.017459_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.017459_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1023\/B:PHAM.0000026422.06207.33","article-title":"Characterization of the cellular localization, expression level, and function of SNP variants of MRP2\/ABCC2","volume":"21","author":"Hirouchi","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.107.017459_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","article-title":"Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the anti-viral drugs adefovir and tenofovir","volume":"71","author":"Imaoka","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.107.017459_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1124\/dmd.105.009175","article-title":"Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans","volume":"34","author":"Ishiguro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.017459_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.107.017459_bib8","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"10.1124\/dmd.107.017459_bib9","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1128\/MCB.24.17.7612-7621.2004","article-title":"Mrp4 confers resistance to topotecan and protects the brain from chemotherapy","volume":"24","author":"Leggas","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1124\/dmd.107.017459_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.107.017459_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1124\/jpet.105.085589","volume":"314","author":"Matsushima","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.017459_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/dmd.105.008888","article-title":"OATP1B1, OATP1B3, and Mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker","volume":"34","author":"Nakagomi-Hagihara","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.017459_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.017459_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1124\/jpet.106.113076","article-title":"Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices","volume":"321","author":"Nozaki","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.017459_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pharmthera.2005.07.005","article-title":"Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion","volume":"109","author":"Robertson","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.107.017459_bib16","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1681\/ASN.V1061159","article-title":"Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma","volume":"10","author":"Schaub","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.107.017459_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/00912700122010393","article-title":"Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects","volume":"41","author":"Schwocho","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.107.017459_bib18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/dmd.105.004622","article-title":"Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans","volume":"33","author":"Shimizu","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.017459_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2133\/dmpk.18.33","article-title":"Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes","volume":"18","author":"Shitara","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.107.017459_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1124\/jpet.105.088104","article-title":"A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters","volume":"315","author":"Tahara","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.017459_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/bbrc.2000.2922","article-title":"Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family","volume":"273","author":"Tamai","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.107.017459_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)00446-6","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.107.017459_bib23","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2165\/00003495-200262090-00005","article-title":"Olmesartan medoxomil","volume":"62","author":"Warner","year":"2002","journal-title":"Drugs"},{"key":"10.1124\/dmd.107.017459_bib24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (MULTI) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J Pharmacobiodyn"},{"key":"10.1124\/dmd.107.017459_bib25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.105.008938","article-title":"Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans","volume":"34","author":"Yamashiro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.017459_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1527-3466.2004.tb00147.x","article-title":"Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist","volume":"22","author":"Yoshida","year":"2004","journal-title":"Cardiovasc Drug Rev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624015071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624015071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.017459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:26:53Z","timestamp":1739896013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624015071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0090955624015071"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.017459","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.017459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}